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The WT1 transcription factor regulates SRY expression during the
initial steps of the sex determination process in humans, activating a
gene cascade leading to testis differentiation. In addition to causing
Wilms’ tumor, mutations in WT1 are often responsible for urogenital
defects in men, while SRY mutations are mainly related to 46,XY pure
gonadal dysgenesis. In order to evaluate their role in abnormal testicu-
lar organogenesis, we screened for SRY and WT1 gene mutations in 10
children with XY partial gonadal dysgenesis, 2 of whom with a history
of Wilms’ tumor. The open reading frame and 360 bp of the 5' flanking
sequence of the SRY gene, and the ten exons and intron boundaries of
the WT1 gene were amplified by PCR of genomic DNA. Single-strand
conformation polymorphism was initially used for WT1 mutation
screening. Since shifts in fragment migration were only observed for
intron/exon 4, the ten WT1 exons from all patients were sequenced
manually. No mutations were detected in the SRY 5' untranslated
region or within SRY open-reading frame sequences. WT1 sequencing
revealed one missense mutation (D396N) in the ninth exon of a patient
who also had Wilms’ tumor. In addition, two silent point mutations
were found in the first exon including one described here for the first
time. Some non-coding sequence variations were detected, represent-
ing one new (IVS4+85A>G) and two already described (-7ATG T>G,
IVS9-49 T>C) single nucleotide polymorphisms. Therefore, muta-
tions in two major genes required for gonadal development, SRY and
WT1, are not responsible for XY partial gonadal dysgenesis.
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Introduction
XY gonadal dysgenesis is a disorder of
sexual determination and differentiation that
includes a complete (pure) and a partial form.
Patients with a 46,XY karyotype and pure
gonadal dysgenesis have a female pheno-
type with full development of unambiguous
female genitalia, well-developed Müllerian
structures and streak gonads. In contrast,
patients with 46,XY partial gonadal dysgen-
esis are characterized by partial testicular
differentiation, low levels of testosterone,
ambiguous genitalia, and persistence of
Müllerian structures. Patients with both forms
are at increased risk for gonadal neoplastic
transformation (1). Depending on the sever-
ity of testicular dysgenesis, anti-Müllerian
hormone levels may be low or undetectable
in patients with abnormal testicular determi-
nation (2,3). Gonadal histology is typically
characterized by poorly developed seminif-
erous tubules surrounded by wavy ovarian
stroma, but may range from apparently nor-
mally differentiated testes to streak gonads.
According to Berkovitz et al. (4), patients
with 46,XY partial gonadal dysgenesis may
present a wide range of characteristics de-
pending on the extent of testicular develop-
ment and they may have either bilateral
dysgenetic testes or one dysgenetic testis
and one streak gonad. Scolfaro et al. (5)
described this histological variability in a
series of 13 children with partial gonadal
dysgenesis.
Sex-determining genes direct the fate of
the bipotential gonad to either testis or ovary.
They can be categorized into transcription
factors involved throughout gonadal mor-
phogenesis (e.g., SF1, WT1), inducers of
testicular development (SRY, SOX9), and
“anti-testis” genes and potential promoters
of ovarian development (DAX1, WNT4). All
of these genes are expressed in the develop-
ing genital ridges, and their products interact
with each other as part of a complex genetic
pathway leading to gonadal differentiation
into one sex or the other (6).
Mutations in or abnormal expression of
any of such genes will impair the formation
of testes in an XY background or the forma-
tion of ovaries in an XX background (6).
Indeed, mutations in the SRY (sex determin-
ing region on the Y chromosome), the major
gene required for male sex determination,
have been reported to account for 20 to 67%
of cases of 46,XY pure gonadal dysgenesis
(7). In most cases the mutations are located
within the high mobility group box, which is
a DNA-binding domain essential for SRY
function as a transcriptional regulator. Only
seven SRY mutations of the 44 described so
far are found outside this domain (8). Nucleo-
tide changes in the 5' untranslated region
(UTR) flanking sequence of the SRY gene
seem not to be a major cause of disturbance
in the male differentiation pathway but a few
mutations that might affect SRY expression
have been reported in XY females (9).
WT1 (Wilms’ tumor gene 1) encodes a
transcription factor containing four “zinc-
finger” motifs which binds to and acts syner-
gistically with SRY to activate transcription
from promoters containing SRY-binding sites
(10), being also required for the normal de-
velopment and function of the urogenital
tract (11,12). The complexity of WT1 action
is reflected at the molecular level, since up to
24 different isoforms may result from a com-
bination of alternative translational sites, al-
ternative RNA splicing and RNA editing
(13). Constitutional mutations are associ-
ated with familial Wilms’ tumor and syn-
dromes such as Denys-Drash syndrome char-
acterized by nephropathy, genital anomalies
and often a predisposition to Wilms’ tumor
(12). Transcripts of the WT1 gene are de-
tected in the gonadal ridge as early as 6
weeks postconception in human embryos,
before testis determination (14). According
to Fuqua et al. (15), mutations in the WT1
gene may result in abnormalities of gonadal
ridge formation that delay testis determina-
tion. Since the WT1 gene is also expressed in
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the gonadal ridge after testis determination
(14), defects in WT1 may also delay the
differentiation after SRY expression.
In this report, we present the data ob-
tained for 10 patients with a diagnosis of
partial gonadal dysgenesis who were inves-
tigated for mutations in the SRY and WT1
coding and non-coding sequences.
Patients and Methods
The series consisted of 10 patients with a
diagnosis of partial gonadal dysgenesis and
a 46,XY karyotype. They were examined by
the members of the Grupo Interdisciplinar
de Estudos da Determinação e Diferenciação
do Sexo at Hospital das Clínicas, Universi-
dade Estadual de Campinas (UNICAMP),
Campinas, SP, Brazil. The protocol was ap-
proved by the Ethics Committee of Faculda-
de de Ciências Médicas, UNICAMP. In-
formed consent was obtained from the par-
ents of the children included in the study.
The diagnosis of XY partial gonadal dys-
genesis was based on findings of ambiguous
genitalia and bilateral cryptorchidism, low
levels of testosterone and anti-Müllerian
hormone (Table 1). All patients showed ev-
idence of Müllerian duct derivatives, which
was confirmed by laparoscopy.
Patients 9 and 10 had a personal history
of unilateral Wilms’ tumor. Patient 10 also
had progressive renal failure and died at 13
months of age; at autopsy, kidney evaluation
revealed diffuse mesangial sclerosis. This
patient had a Denys-Drash syndrome pheno-
type. No patient had a family history of
intersex.
The diagnosis of gonadal dysgenesis was
confirmed by a careful histologic and mor-
phometric evaluation of the gonads based on
the following criteria: gonadal position, mean
tubular diameter, number of germ cells, num-
ber of Sertoli cells, and presence or absence
of Müllerian and Wolffian duct derivatives.
These results were published in a report by
Scolfaro et al. (5), in which the present pa-
tients 1 to 9 were patients 2, 3, 4, 6, 7, 8, 9,
13, and 12, respectively. At autopsy, bilat-
eral streak gonads were found in patient 10.
Genomic DNA was extracted from pe-
ripheral blood leukocytes by standard tech-
niques (17). The SRY open reading frame
(ORF) was amplified with primers XES10
Table 1. Genital phenotype and hormonal data of 10 children with 46,XY partial gonadal dysgenesis who
participated in the study.
Patient Age External Gonadal position AMH (normal values T FSH LH
(months) genitalia1 (right/left)  for age) (pmol/l) (nmol/l)2 (IU/l)3 (IU/l)4
1 108 2 A/A (left   = streak) 114 (234-438) 0.7 5.4 0.9
2 30 2 I/I 52 (360-638) <0.3 1.2 0.6
3 0.5 3 I/I 98 (251-679) 1.75 3.9 0.8
4 92 2 I/A (left = streak) 113 (234-438) <0.3 5.8 0.8
5 78 2 I/- 73 (309-566) 1.0 6.3 1.0
6 13 2 I/I 107 (360-638) <0.3 1.0 0.5
7 20 4 I/A (left = streak) 11 (360-638) <0.3 1.5 1.1
8 44 3 I/A (left = streak) 71 (360-638) <0.3 0.9 0.9
9# 29 3 A/A 116 (360-638) 3.1 0.7 0.3
10# 12 2 I/A NP <0.3 7.8 3.4
AMH = anti-Müllerian hormone (2); T = total testosterone; FSH = follicle-stimulating hormone; LH =
luteinizing hormone; A = abdominal; I = inguinal canal; -, not found; NP = not performed.
1According to the classification of Quigley et al. (16). 2Total testosterone level after the human chorionic
gonadotropin stimulation test (normal value: above 1.4 nmol/l). 3Normal values of prepubertal FSH: 0.1-1.4
IU/l. 4Normal values of prepubertal LH: 0.1-1.0 IU/l. 5Basal total testosterone level. #Patient with a past
history of Wilms’ tumor.
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and XES11 described by Hawkins et al. (18).
PCR amplifications were performed by the
method of Assumpção et al. (8). For the
amplification of the 360-bp SRY 5' flanking
sequence, encompassing the SRY putative
core promoter, we used the primers and PCR
conditions described by Schmitt-Ney et al.
(19). Five microliters of PCR amplification
products were submitted to direct sequenc-
ing with the Thermo-sequenase radiolabeled
terminator cycle sequencing kit (Amersham-
Pharmacia Biotech, Uppsala, Sweden). Se-
quencing was carried out twice with prod-
ucts from different PCR procedures and with
both sense and antisense primers to confirm
the results.
The 10 exons and their flanking regions
of the WT1 gene were amplified by PCR
from genomic DNA with primers described
in Table 2. Due to its long size and some
difficulties in fragment amplification, 3 dif-
ferent primer pairs were used for exon 1. The
PCR amplifications were performed as de-
scribed before for SRY (8), except that DMSO
was omitted. After a first denaturation step
(10 min, 95ºC), the cycling profile was: 95ºC,
1 min; 54-64ºC, 1 min; 72ºC, 1 min (30
cycles), followed by 10 min at 72ºC (final
extension). The PCR products were ana-
lyzed in 1% ethidium bromide-stained aga-
rose gels to determine the size of the frag-
ments. Amplified products were screened
for sequence variations by non-radioactive
single-strand conformation polymorphism
(SSCP) analysis. Electrophoresis was per-
formed with the PhastSystem™ (Pharmacia
Biotech) using 12.5 and 20% non-denatur-
ing polyacrylamide homogeneous Phastgel
with PhastGel SDS and native buffer strips
and the gels were silver stained. Direct se-
quencing of PCR products was carried out in
two separate reactions using sense and anti-
Table 2. Primers designed for WT1 amplification.
Exon Sequences 5'-3’ (nt positions) Annealing Size GenBank accession
temperature (ºC) (bp)  number
1 1S - AGCCAGAGCAGCAGGGAGT (665-683) 64 278 X61631
1AS - ACGACCCGTAAGCCGAAGC (922-940)
1BS - ATGGGCTCCGACGTGC (790-805) 54 215
1BAS - ATGAAGGAGTGAGGCGG (988-1004)
1CS - TTCGGCTTACGGGTCGTTGG (924-943) 62 397
1CAS - CAAAAGGGGTAGGAGAGGGG (1301-1320)
2 2S - CCGTCTTGCGAGAGCACC (3-20) 58 262 M80218
2AS - CTAATTTGCTGTGGGTTAGG (245-264)
3 3S - GCTCAGGATCTCGTGTCTCC (5-24) 64 318 M80219
3AS - GCCTCCAAGACCCAGCAT (305-322)
4 4S - CAGTTGTGTATTATTTTGTGG (235-255) 56 285 X61633
4AS - AACTAGGGGAAGGAGGAAA ( 502-520)
5 5S - CCACTCCCCACCTCTTC (190-206) 56 115 X61634
5AS - CGCCATTTGCTTTGCC (290-305)
6 6S - CCTTTTTCCCTTCTTTG (159-175) 52 179 X61635
6AS - TAAGTAGGAAGAGGCAGT (320-337)
7 7S - GCTTAAAGCCTCCCTTC (157-173) 54 231 X61636
7AS - CTTGAACCATGTTTGCCC (370-387)
8 8S - GAGATCCCCTTTTCCAG (178-194) 56 177 X61637
8AS - CACAGCTGCCAGCAATG (338-354)
9 9S - CTCACTGTGCCCACATTG (868-885) 58 210 X61637
9AS - CAATTTCATTCCACAATAG (1059-1077)
10 10S - ACTTCACTCGGGCCTTGATAG (149-169) 62 276 X61638
10AS - AGTGGAGAGTCAGACTTGAAAG (403-424)
nt = nucleotide; bp = base pairs.
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sense primers as described above.
Results
The patients with 46,XY partial gonadal
dysgenesis did not present any mutation
within the SRY 5' UTR or the SRY ORF
sequence, whereas SSCP analysis of the WT1
gene revealed shifts only for the fragments
obtained with primers 4S and 4AS. After
sequencing, it was concluded that the shifts
observed in the SSCP gels arose as a result of
a non-described nucleotide variation in the
3' flanking region of the fourth exon, located
within intron 4 (IVS4+85A>G). Since the
SSCP technique was unable to detect se-
quence variations in the majority of ampli-
fied fragments, sequencing of the whole
WT1 coding region was performed. This pro-
cedure revealed three single nucleotide
polymorphisms (SNPs) already described
in normal populations (20) (rs22344582,
rs1799925 and rs1799937 according to the
Single Nucleotide Polymorphism Database)
and a new 163G>A silent point mutation at
codon 54 (Pro54Pro; patients 3, 5 and 8).
Table 3 shows the patients’ genotypes for
these polymorphic sites. The only patho-
genic mutation in this study was a nucleotide
change (1186G>A), which was found in het-
erozygous condition in patient No. 10. This
transition is located within the ninth exon
and causes a missense mutation which
changes the predicted aspartic acid in codon
396 to asparagine (D396N).
Discussion
The absence of SRY mutations observed
in the present study reinforces previous lit-
erature data which suggest that SRY muta-
tions in patients with partial gonadal dysgen-
esis are much less frequent than in XY pure
gonadal dysgenesis (22). Among the 44 dif-
ferent SRY ORF mutations reported to date,
only three were associated with XY partial
gonadal dysgenesis (reviewed by Assumpção
et al., 8). One of them was a variant sequence
(S18N) also found in normal relatives of the
patient (23). The second (R30I) was found in
affected and non-affected members of a fam-
ily, including the father, two siblings with
partial gonadal dysgenesis, a phenotypic fe-
male with pure gonadal dysgenesis, and three
Table 3. WT1 single nucleotide polymorphism genotypes in 10 children with partial gonadal dysgenesis.
Patient Exon 1 Intron 4 Intron 9
+85 -49
rs223445821 rs17999251 238577032 238402282 rs17999371
G>T C>T  G>A A>G T>C
(-7 from first ATG) (Pro42Pro) (Pro54Pro)
1 T/T C/C A/A A/A C/C
2 T/T C/C G/G A/G T/T
3 G/G T/T G/G G/G C/C
4 T/T T/T G/G A/G C/C
5 T/T C/C G/G A/G C/C
6 T/T T/T G/G A/A T/T
7 T/T C/C G/G G/G T/T
8 T/T C/C A/A G/G T/T
9 T/T C/C A/A A/A T/T
10 G/G T/T G/G A/A T/T
Normal male control T/T C/C G/G A/G T/T
1rs = reference sequence number according to http://www.ncbi.nlm.nih.gov/SNP (20). 2Numbering accord-
ing to H. sapiens chromosome 11 genomic contig (gi|29807454|ref|NT_009237.15|Hs11_9394[29807454] –
http://www.ncbi.nlm.nih.gov/ (21).
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non-affected male siblings (8). Both muta-
tions are located in the non-high motility
group box, while the third one (Y129N) is
located at C-terminal of the high motility
group box sequence (24). In vitro studies
revealed that R30I mutant protein was poorly
phosphorylated and showed reduced DNA-
binding capacity (7), while the Y129N mu-
tant exhibited altered protein-protein inter-
actions (24). In addition, a case of XY partial
gonadal dysgenesis with a de novo intersti-
tial deletion at the 3' end of the SRY ORF was
reported by McElreavey et al. (25), who
proposed that this deletion could be respon-
sible for the abnormal gonadal development
by diminishing SRY expression.
To date, no nucleotide changes in the 5'
UTR flanking sequence of the SRY gene
have been reported in XY partial gonadal
dysgenesis. A paternally inherited 3-bp dele-
tion in the SRY 5’UTR Sp1 binding site has
been demonstrated in a 46,XY female with
pure gonadal dysgenesis (Assumpção JG,
Maciel-Guerra AT, Marques-de-Faria AP,
Guerra Jr G, Scolfaro MR and De Mello MP,
unpublished data). The patient’s father had
surgically corrected hypospadias and peno-
scrotal fusion as a child and other affected
relatives with genital ambiguity have been
reported in this family. These findings sug-
gest that, although rare, SRY mutations should
be screened in cases of partial gonadal dys-
genesis, especially if familial recurrence of
genital ambiguity is reported.
In the present study, analysis of the WT1
gene revealed the D396N deleterious muta-
tion in one of the patients with unilateral
Wilms’ tumor (patient No. 10). This muta-
tion had already been described in patients
with Denys-Drash syndrome (26,27), being
the third most frequent mutation reported in
the Universal WT1 mutation database (28).
According to Little and Wells (29), the Denys-
Drash phenotype often arises from the alter-
ation of one allele by a missense point muta-
tion, usually in the zinc finger binding do-
main of WT1. The second and third zinc
finger regions, encoded by exons 8 and 9, are
considered to be hot spots for mutations in
patients with typical Denys-Drash nephrop-
athy (30). Based on experimental evidence,
some investigators have claimed that the
Denys-Drash syndrome mutations behave in
a dominant-negative fashion (27,31,32),
while others have proposed that heterozy-
gous point mutations cause functional loss
of one WT1 allele; therefore, haploinsuffi-
ciency may be responsible for the phenotype
(33).
The constitutional heterozygous missense
D396N, identified in patient 10 described
here, affects the third zinc finger region of
the protein. It has been shown that D396N
has a slightly reduced binding affinity for
selected DNA sequences when compared
with the wild-type WT1 (34). Thus, the clini-
cal phenotype of Denys-Drash syndrome in
our patient may be associated with a modest
reduction in the DNA binding affinity of
WT1, either in a near-haploinsufficiency
condition or in a dominant-negative fashion.
Moreover, the persistence of the Müllerian
ducts in this patient may indicate a MIS gene
deregulation, since WT1 is an essential fac-
tor for the transactivation of MIS promoter
(35). Indeed, co-transfection experiments
with several zinc finger mutant WT1s (D396N
included) with either SOX9 or SF1 failed to
activate synergistically reporter constructs
containing the MIS promoter (36). WT1 is
also considered a key regulator of the vis-
ceral epithelial cells (podocytes) of the ma-
ture glomerulus function, by repressing or
activating PAX2 expression (37,38) and bind-
ing to conserved elements within the
Podocalyxin gene promoter (39). Reduced
expression levels leading to impairment of
the podocytes cause crescentic glomerulo-
nephritis and mesangial sclerosis (40) and
could explain the early manifestations of
nephrotic syndrome in our patient, which
began after surgical excision of a left-sided
Wilms’ tumor at the age of 12 months. In a
retrospective study of 12 patients treated for
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WT1 gene-related disorders, Auber et al.
(30) reported that in Denys-Drash syndrome
patients, proteinuria occurred very early and
diffuse mesangial sclerosis or mesangial hy-
perplasia was the cause of end-stage renal
disease, in the presence of missense point
mutations affecting the third zinc finger.
We were unable to demonstrate any path-
ogenic mutation after sequencing the 10 ex-
ons and the corresponding flanking regions
of the WT1 gene of patient 9 described in this
paper, who also had a Wilms’ tumor at age
four but remained free of renal disease after
5 years of follow-up. However, neither a
WT1 intragenic deletion nor mutations in the
promoter region that could significantly af-
fect the transcription rate were excluded in
the present case. Baird et al. (27) reported a
similar case of an atypical XY Denys-Drash
syndrome female patient with Wilms’ tumor
and ambiguous genitalia, but no nephropa-
thy or WT1 gene mutations, arguing that
such cases raise the possibility of the exist-
ence of other genes which may also predis-
pose to this clinical condition.
No WT1 mutations were detected in pa-
tients with partial gonadal dysgenesis with-
out renal abnormalities or Wilms’ tumor
manifestations (patients 1 to 8). Among the
five SNP identified in some of these patients,
three can be found in the SNP database, with
allelic frequencies obtained from samples of
90 individuals (20). For the WT1 SNP lo-
cated at -7 from the first ATG (G>T), the
“G” and “T” allele frequencies are of 0.722
and 0.278, respectively. An inverted rate
was found for our patients, with the “T”
allele being the most frequent one (0.8) but
the small size of our sample precludes any
conclusion. The “C” and “T” allelic frequen-
cies reported for the WT1 SNP located at
exon 1 are 0.711 and 0.289, respectively. In
our sample, the frequencies were of 0.6 and
0.4 for the “C” and “T” alleles, respectively.
The third SNP (IVS9-49 T>C) has frequen-
cies of 0.55 and 0.45 reported for the “T”
and “C” alleles, respectively. The “T” and
“C” allelic frequencies in our patients were
of 0.6 and 0.4, respectively. Two not yet
described sequence variations were identi-
fied in the present study, possibly represent-
ing new polymorphisms if we take into ac-
count the genotypic variation observed in
the patient sample. Although the pathogenic
significance of WT1 SNPs is largely un-
known, it is possible to propose that some
haplotypes could play a role in the efficiency
of mRNA processing or translation due to
secondary structures.
Our results suggest that WT1 gene muta-
tions are not a common cause of 46,XY
partial gonadal dysgenesis in the absence of
renal abnormalities or Wilms’ tumor mani-
festations. In conclusion, although mutations
in the two major genes required for male
gonadal development account for a minority
of cases of XY partial gonadal dysgenesis,
genetic analysis of the WT1 gene should be
performed in these patients looking for
Wilms’ tumor or nephropathy risk factor.
This clearly indicates that mutations at other
chromosomal loci should be investigated in
order to elucidate these complex clinical
situations.
References
1. Robboy SJ, Miller T, Donahoe PR, Jahre C, Welch WR, Haseltine
FP, Miller WA, Atkins L & Crawford JD (1982). Dysgenesis of
testicular and streak gonads in the syndrome of mixed gonadal
dysgenesis: perspective derived from clinicopathologic analysis of
twenty-one cases. Human Pathology, 13: 700-716.
2. Rey RA, Belville C, Nihoul-Fekete C et al. (1999). Evaluation of
gonadal function in 107 intersex patients by means of serum
antimullerian hormone measurement. Journal of Clinical Endocri-
nology and Metabolism, 84: 627-631.
3. Stuchi-Perez EG, Lukas-Croisier C, De Castro M, Baptista MTM,
Scolfaro MR, Marques-de-Faria AP, Hackel C, Maciel-Guerra AT &
Guerra Jr G (2000). Evaluation of the tubular and the interstitial
functions of the testis in 46,XY patients with ambiguous genitalia.
Journal of Pediatric Endocrinology and Metabolism, 13: 605-612.
24
Braz J Med Biol Res 38(1) 2005
E.B. Tagliarini et al.
4. Berkovitz GD, Fechener MD, Zacur HW, Rock JÁ, Snyder III MD,
Migeon CJ & Perlman EJ (1991). Clinical and pathologic spectrum of
46,XY gonadal dysgenesis: its relevance to the understanding of
sex differentiation. Medicine, 10: 375-383.
5. Scolfaro MR, Cardinalli IA, Gabas Stuchi-Perez E, De Mello MP,
Assumpção JG, Baptista MTM, Silva JMB, Maciel-Guerra AT &
Guerra Jr G (2001). Morphometry and histology of gonads from 13
children with dysgenetic male pseudohermaphroditism. Archives of
Pathology and Laboratory Medicine, 125: 652-656.
6. MacLaughlin DT & Donahoe PK (2004). Sex determination and
differentiation. New England Journal of Medicine, 350: 367-378.
7. Uehara S, Hashiyada M, Sato K, Nata M, Funato T & Okamura K
(2002). Complete XY gonadal dysgenesis and aspects of the SRY
genotype and gonadal tumor formation. Human Genetics, 47: 279-
284.
8. Assumpção JG, Benedetti CE, Maciel-Guerra AT, Guerra Jr G,
Baptista MTM, Scolfaro MR & De Mello MP (2002). Novel muta-
tions affecting SRY DNA-binding activity: the HMG box N65H asso-
ciated with 46,XY pure gonadal dysgenesis and the familial non-
HMG box R30I associated with variable phenotypes. Journal of
Molecular Medicine, 80: 782-790.
9. Poulat F, Desclozeaux M, Tuffery S, Jay P, Boizet B & Berta P
(1998). Mutation in the 5' noncoding region of the SRY gene in an
XY sex-reversed patient. Human Mutation, 1 (Suppl 1): S192-S194.
10. Matsuzawa-Watanabe Y, Inoue J & Semba K (2003). Transcriptional
activity of testis-determining factor SRY is modulated by the Wilms’
tumor 1 gene product, WT1. Oncogene, 22: 5956-5960.
11. Shimamura R, Fraizer GC, Trapman J, Lau IC & Saunders GF (1997).
The Wilms’ tumor gene WT1 can regulate genes involved in sex
determination and differentiation: SRY, Müllerian-inhibiting sub-
stance, and the androgen receptor. Clinical Cancer Research, 3:
2571-2580.
12. Heathcott RW, Morison IM, Gubler MC, Corbett R & Reeve AE
(2002). A review of the phenotypic variation due to the Denys-Drash
syndrome-associated germline WT1 mutation R362X. Human Mu-
tation, 19: 462.
13. Wagner KD, Wagner N & Schedl A (2003). The complex life of WT1.
Journal of Cell Science, 116: 1653-1658.
14. Pritchard-Jones K, Fleming S, Davidson D et al. (1990). The candi-
date Wilms’ tumour gene is involved in genitourinary development.
Nature, 346: 194-197.
15. Fuqua JS, Sher ES, Perlman EJ, Urban MD, Ghahremani M, Pelletier
J, Migeon CJ, Brown TR & Berkovitz GD (1996). Abnormal gonadal
differentiation in two subjects with ambiguous genitalia, Müllerian
structures, and normally developed testes: evidence for a defect in
gonadal ridge development. Human Genetics, 97: 506-511.
16. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EMD
& French FS (1995). Androgen receptor defects: historical, clinical,
and molecular perspectives. Endocrine Reviews, 16: 271-321.
17. Sambrook J, Fristsch EF & Maniatis TE (1989). Molecular Cloning: A
Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor,
NY, USA.
18. Hawkins JR, Taylor A, Berta P, Levilliers J, Van der Auwera B &
Goodfellow PN (1992). Mutational analysis of SRY : nonsense and
missense mutations in XY sex reversal. Human Genetics, 88: 471-
474.
19. Schmitt-Ney M, Thiele H, Kaltwasser P, Bardoni B, Cisternino M &
Scherer G (1995). Two novel SRY missense mutations reducing
DNA binding identified in XY females and their mosaic fathers.
American Journal of Human Genetics, 56: 862-869.
20. Single Nucleotide Polymorphism Database - dbSNP. http://
www.ncbi.nlm.nih.gov/SNP/index.html. Accessed November 28,
2003.
21. National Center for Biotechnology Information Nucleotide Data-
base. http://www.ncbi.nlm.nih.gov/. Accessed September 12, 2003.
22. Hawkins JR, Taylor A, Goodfellow PN, Migeon CJ, Smith KD &
Berkovitz GD (1992). Evidence for increased prevalence of SRY
mutations in XY females with complete rather than partial gonadal
dysgenesis. American Journal of Human Genetics, 51: 979-984.
23. Domenice S, Nishi MY, Billerbeck AEC et al. (1998). A novel mis-
sense mutation (S18N) in the 5' non-HMG box region of the SRY
gene in a patient with partial gonadal dysgenesis and his normal
male relatives. Human Genetics, 102: 213-215.
24. Baud S, Margeat E, Lumbroso S, Paris F, Sultan C, Royer C & Poujol
N (2002). Equilibrium binding assays reveal the elevated stoichiom-
etry and salt dependence of the interaction between full-length
human sex-determining region on the Y chromosome (SRY ) and
DNA. Journal of Biological Chemistry, 277: 18404-18410.
25. McElreavey K, Vilain E, Barbaux S et al. (1996). Loss of sequences
3' to the testis-determining gene, SRY, including the Y pseudoauto-
somal boundary associated with partial testicular determination.
Proceedings of the National Academy of Sciences, USA, 93: 8590-
8594.
26. Pelletier J, Bruening W, Kashtan CE et al. (1991). Germline muta-
tions in the Wilms’ tumor suppressor gene are associated with
abnormal urogenital development in Denys-Drash syndrome. Cell,
67: 437-447.
27. Baird PN, Santos A, Groves N, Jadresic L & Cowell JK (1992).
Constitutional mutations in the WT1 gene in patients with Denys-
Drash syndrome. Human Molecular Genetics, 1: 301-305.
28. Jeanpierre C, Béroud C, Niaudet P & Junien C (1998). Software and
database for the analysis of mutations in the human WT1 gene.
Nucleic Acids Research, 26: 271-274.
29. Little M & Wells C (1997). A clinical overview of WT1 gene muta-
tions. Human Mutation, 9: 209-225.
30. Auber F, Lortat-Jacob S, Sarnacki S, Jaubert F, Salomon R, Thibaud
E, Jeanpierre C & Cihoul-Fékété C (2003). Surgical management
and genotype/phenotype correlations in WT1 gene-related diseases
(Drash, Frasier syndromes). Journal of Pediatric Surgery, 38: 124-
129.
31. Bardeesy N, Zabel B, Schmitt K & Pelletier J (1994). WT1 mutations
associated with incomplete Denys-Drash syndrome define a do-
main predicted to behave in a dominant-negative fashion. Genom-
ics, 21: 663-665.
32. Moffet P, Bruening W, Nakagama H, Bardeesy N, Housman D,
Housman DE & Pelletier J (1995). Antagonism of WT1 activity by
protein self-association. Proceedings of the National Academy of
Sciences, USA, 92: 11105-11109.
33. Hossain A & Saunders GF (2001). The human sex-determining gene
SRY is a direct target of WT1. Journal of Biological Chemistry, 18:
16817-16823.
34. Borel F, Barilla KC, Hamilton TB, Iskandar M & Romaniuk PJ (1996).
Effects of Denys-Drash syndrome point mutations on the DNA
binding activity of the Wilms’ tumor suppressor protein WT1. Bio-
chemistry, 35: 12070-12076.
35. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN,
Hammer GD & Ingraham H (1998). Wilms’ tumor 1 and Dax-1
modulate the orphan nuclear receptor SF-1 in sex-specific gene
expression. Cell, 93: 445-454.
36. Hossain A & Saunders GF (2003). Role of Wilms’ tumor 1 (WT1) in
the transcriptional regulation of the Müllerian-Inhibiting Substance
Promoter. Biology of Reproduction, 69: 1808-1814.
25
Braz J Med Biol Res 38(1) 2005
SRY and WT1 genes in XY partial gonadal dysgenesis
37. Favor J, Sandulache R, Neuhauser KA et al. (1996). The mouse Pax2
(1Neu) mutation is identical to a human PAX2 mutation in a family
with renal-coloboma syndrome and results in developmental de-
fects of the brain, ear, eye and kidney. Proceedings of the National
Academy of Sciences, USA, 93: 13870-13875.
38. Ryan G, Steele Perkins V, Morris JR, Rauscher FJ & Dressler GR
(1995). Repression of Pax-2 by WT1 during normal kidney develop-
ment. Development, 121: 867-875.
39. Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W & Haber DA
(2001). WT1 regulates the expression of the major glomerular
podocyte membrane protein Podocalyxin. Current Biology, 11: 1805-
1809.
40. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A,
Hastie ND & Schedl A (2002). WT1 is a key regulator of podocyte
function: reduced expression levels cause crescentic glomerulone-
phritis and mesangial sclerosis. Human Molecular Genetics, 11:
651-659.
